SEARCH
Industry Partners
Prairie Swine Centre is an affiliate of the University of Saskatchewan
Prairie Swine Centre is grateful for the assistance of the George Morris Centre in developing the economics portion of Pork Insight.
Financial support for the Enterprise Model Project and Pork Insight has been provided by:
Canada’s Industry & Regulatory Framework: An ongoing policy initiative to enhance responsible use of Veterinary Antimicrobials
Posted in: Pork Insight Articles, Production by student on June 29, 2018
Author: Dr. Egan Brockhoff
Reference: Banff Pork Seminar Proceedings 2018
Summary: Canadian law is working to lay a strong framework for regulations surrounding antimicrobials. With regards to the Canadian Pork industry, they have been working closely with stakeholders to ensure that their voices are heard. There has currently been six core regulatory and policy initiatives:
1. Increasing oversight on importance of veterinary drugs (Own Use Importation or OUI)
2. Increasing oversight on importation and quality of active pharmaceutical ingredients (APIs)
3. Mandatory reporting of sales volume from manufactures and importers to support antimicrobial use surveillance
4. Facilitating access to low risk veterinary health products (VHPs), as additional tools for the maintenance of animal health and welfare
5. Removing growth promotion claims from medically-important antimicrobials (MIAs)
6. Increasing veterinary oversight over all MIAs (Prescription status switch)
Regulation came into play on November 13th, 2017, which prohibits importation of drugs not approved in Canada other than products that represent an acceptable risk to food safety and public health. These products will be maintained on “List B” by Health Canada and will follow specific criteria.
Currently there are no provision associated with low risk veterinary health products. VHPs will be specified for a special and animal type and will only be able to state that they, “maintain or promote the health and welfare of” the define species.
As of May 17th, 2018 all APIs must be manufactured following Good Manufacturing Practices (GMPs) used in human medicine and manufactures will be required to have a Drug Establishment License (DEL).
*** As of March 31st 2019, all sales data from the previous year must be reported ***
Canadian Industry and Framework